Clinical Characteristics of 55 Cases of Deaths with COVID-19 Pneumonia in Wuhan, China: Retrospective Case Series

Yao, Tao; Gao, Yan; Cui, Qin; Shen, Jing; Peng, Bo; Chen, Yan; Li, Jiansheng; Huang, Chao; He, Chunping; Pu, Jie; Wei, Jian‐Jun; Zhan, Yanqiang; Yan, Jie; Tian, Jian; Liu, Zhichao

doi:10.2139/ssrn.3550019

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Total 36 of the selected studies presented death counts following COVID-19 disease among patients with or without specific one or more morbidities. Four included studies (Du et al [29], Zhang et al [30], Kim et al [31] and Yao et al [32]) were conducted only for dead COVID-19 patients and reported the status of pre-existing morbidities before their deaths. All studies were of moderate to high quality (Supplementary Table 6-7).…”

Section: Resultsmentioning

confidence: 99%

Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis

Khan

Mustagir

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 , the most hectic pandemic of the era, is increasing exponentially and taking thousands of lives worldwide. This study aimed to assess the prevalence of pre-existing morbidities among COVID-19 infected patients and their mortality risks against each type of pre-existing morbidity category. Methods:To conduct this systematic review and meta-analysis, Medline, Web of Science, Scopus, and CINAHL databases were searched using specified relavent keywords. Further searches were conducted using the reference list of the selected studies, renowned pre-print servers (e.g., medRxiv, bioRixv, SSRN), and relevant journal websites. Studies written in the English language included if those were conducted among COVID-19 patients with and without comorbidities and presented survivor vs. non-survivor counts or hazard/odds of deaths or survivors against types of pre-existing morbidities. Comorbidities reported in the selected studies were grouped into eight categories. The pooled likelihoods of deaths in each category were estimated using a fixed or random-effect model, based on the heterogeneity assessment. Publication bias was assessed by visual inspection of the funnel plot asymmetry and Egger's regression test. Trim and Fill method was used if there any publication bias was found.

show abstract

Section: Resultsmentioning

confidence: 99%

Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis

Khan

Mustagir

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In this systematic review, 46 articles remained after the final evaluation. [ 3 12 13 14 15 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 ] The majority of articles were case series (73.3%), 25.7% were descriptive retrospective and <1% were descriptive prospective or epidemiological reports. Although most of the articles were originated in China, other articles–about 5%-were from countries such as Japan, the USA, Australia, France, and Taiwan.…”

Section: Resultsmentioning

confidence: 99%

Clinical manifestation, laboratory and radiology finding, treatment and outcomes of COVID-19: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Background: Since December 2019, coronavirus (COVID-19) spread throughout the world. The high rate of infection and its unknown nature led specialists to report the condition of patients. The aim of this study is to systematically review of symptoms, laboratory and radiologic findings, treatment, and outcomes of patients with COVID-19. Materials and Methods: Databases such as PubMed, Embase, Scopus, Web of Science, Google Scholar, and Cochrane were searched. Finally, 46 articles were appropriate for the aim of the study. After quality evaluation, the necessary data were extracted and meta-analysis was performed. Results: 4858 articles were retrieved until March 30, 2020. After screening, the full-text of 46 articles was assessed. Of the reported cases, 31.7% had no comorbidities, 21.4% had high blood pressure, 70.6% had fever, and lymphopenia was reported in 55.2% of patients. For 16% bilateral patchy shadowing in radiography and for 51% ground-glass opacity was reported. Outcomes were remarkable for recover to death. Conclusion: COVID-19 leads to healthcare problems for countries. Nonspecific symptoms have made it difficult for differential diagnoses without computed tomography-scan or corona Test, but they are not available in many countries. Therefore, this systematic review can help health care staff to make decisions based on symptoms, treatments, and outcomes..

show abstract

“…Another study included 140 COVID-19 patients, of whom 42 patients (30%) had hypertension [2]. e prevalence of hypertension in fatal patients was extremely high (42.57%-60%) [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China

Zeng

Sun

et al. 2021

International Journal of Hypertension

View full text Add to dashboard Cite

Increasing evidence has shown an unusual relationship between hypertension and COVID-19, which may not be as simple as previously thought. The purpose of our study was to determine the association of hypertension with the onset and development of COVID-19. A meta-analysis was performed to summarize the prevalence of hypertension in COVID-19 patients, as well as the usage of ACEIs/ARBs. Metaregression analyses were used to evaluate the association of hypertension with disease severity and mortality. PubMed and Google Scholar were searched for relevant studies. A total of 42 studies including 14138 patients were enrolled in the study. The proportion of hypertension in COVID-19 patients in China was 17.7% according to the enrolled studies, while it was 6.0% in a study containing 72314 confirmed cases, which are both much lower than in the general population. All of the data from the 11 provinces in China showed the same tendency. The proportions of hypertension were higher in severe/ICU patients and nonsurvivors than in nonsevere/ICU patients and survivors. The metaregression analyses suggested that both disease severity and risk of death were associated with the incidence of hypertension. A total of 27.6% of COVID-19 patients with hypertension received ACEI/ARB therapy. The proportion of deaths in COVID-19 patients with hypertension treated with ACEIs/ARBs was significantly lower than that in nonuse patients treated with ACEIs/ARBs. In conclusion, hypertension may reduce the infection risk of COVID-19 but increase the risk of developing worse clinical outcomes. The use of ACEIs/ARBs may benefit COVID-19 patients with hypertension.

show abstract

Clinical Characteristics of 55 Cases of Deaths with COVID-19 Pneumonia in Wuhan, China: Retrospective Case Series

Cited by 5 publications

References 0 publications

Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis

Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis

Clinical manifestation, laboratory and radiology finding, treatment and outcomes of COVID-19: A systematic review and meta-analysis

Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China

Contact Info

Product

Resources

About